enGene Holdings Inc. (NASDAQ:ENGNW) Sees Large Drop in Short Interest

enGene Holdings Inc. (NASDAQ:ENGNW) was the recipient of a significant decline in short interest in the month of August. As of August 31st, there was short interest totaling 4,663 shares, a decline of 90.4% from the August 15th total of 48,573 shares. Based on an average daily volume of 13,212 shares, the days-to-cover ratio is presently 0.4 days.

enGene Stock Performance

ENGNW stock traded up $0.02 on Friday, hitting $0.25. 1,813 shares of the company were exchanged, compared to its average volume of 16,250. enGene has a twelve month low of $0.11 and a twelve month high of $4.20. The business’s fifty day moving average is $0.29 and its two-hundred day moving average is $1.08.

About enGene

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.